哮喘-慢阻肺重叠的临床治疗路径
本文综述哮喘-慢阻肺重叠(ACO)患者的治疗框架,指出ACO患者临床结局和医疗资源使用可能比单纯哮喘或慢阻肺更差。文章比较哮喘与慢阻肺治疗的异同,探讨生物标志物(外周血嗜酸性粒细胞、呼出气一氧化氮、血清IgE)在ACO治疗选择中的作用,并讨论单克隆抗体等新疗法在慢阻肺和ACO中的潜在角色。
要点
- ACO患者临床结局和医疗资源使用可能比单纯哮喘或慢阻肺更差。
- 哮喘与慢阻肺治疗的关键区别在于初始治疗选择。
- 生物标志物(外周血嗜酸性粒细胞、呼出气一氧化氮、血清IgE)可辅助ACO治疗选择。
核心结论
- ACO患者临床结局和医疗资源使用可能比单纯哮喘或慢阻肺更差,需建立治疗框架。
- 哮喘与慢阻肺治疗的关键区别在于初始治疗选择,但现有药物使用存在大量重叠。
- 生物标志物(外周血嗜酸性粒细胞、呼出气一氧化氮、血清IgE)可能有助于ACO治疗选择。
研究设计与样本
- 综述类文章,检索范围原文未报告。
主要发现
- ACO患者临床结局和医疗资源使用可能比单纯哮喘或慢阻肺更差。
- 哮喘与慢阻肺治疗的关键区别在于初始治疗选择。
- 已获批用于哮喘的单克隆抗体可能在慢阻肺和ACO患者中发挥作用。
临床怎么用
- 临床中遇到同时具有哮喘和慢阻肺特征的患者,应参考ACO治疗框架选择初始治疗。
- 可利用外周血嗜酸性粒细胞、呼出气一氧化氮、血清IgE等生物标志物辅助ACO治疗选择。
局限性
- ACO的精确界定仍存在争议。
- 综述类文章,检索范围原文未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the last few years, there has been a renewed interest in patients with characteristics of both asthma and COPD. Although the precise definition of asthma-COPD overlap (ACO) is still controversial, patients with overlapping features are frequently encountered in clinical practice, and may indeed have worse clinical outcomes and increased health-care utilization than those with asthma or COPD. Therefore, there is a critical need to set a framework for the therapeutic approach of such patients. There are key distinctions in the therapy between asthma and COPD, particularly regarding the initial choice of therapy. However, there is considerable overlap in the use of existing medications for both diseases. Furthermore, novel therapies approved for asthma, such as monoclonal antibodies, may have a role in patients with COPD and ACO. The use of biomarkers, such as peripheral blood eosinophils, exhaled nitric oxide, and serum IgE, may help in selecting appropriate therapies for ACO. In this review, we provide an overview of available treatments for both asthma and COPD and explore their potential role in the treatment of patients with ACO.
引用
- Maselli DJ, Hardin M, Christenson SA, et al. Clinical Approach to the Therapy of Asthma-COPD Overlap. Chest. 2018. PMID: 30077690. doi:10.1016/j.chest.2018.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。